Business● Low56m ago · Nov 13, 2026, 1:50 AM
Relmada outlines NDV-01 IND submission by year-end 2026 with cash runway through 2029
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Relmada plans to submit its NDV-01 Investigational New Drug application by the end of 2026 and expects to have sufficient cash to operate through 2029.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business11m agoLiberty’s $80 million Brooklyn practice facility won’t be ready for training campNY Post · United StatesBusiness16m agoNeuroPace expects ~15% RNS growth in 2027 as it revises 2026 revenue guidance to $91M-$92MSeeking Alpha TechBusiness16m agoJapan approves energy subsidies of 3.675 billion euros due to Middle East crisisInfobae · ArgentinaBusiness16m agoCibus targets biofragrance peak revenue up to $100M while aiming for rice launch as early as 2028Seeking Alpha Tech